EXACT Therapeutics AS

Company Description

---

We are EXACT Therapeutics AS (“EXACT-Tx”), a clinical-stage biopharmaceutical company developing a novel ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®).

ACT® is a unique approach to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions.

EXACT Therapeutics and our ACT® platform builds on decades of R&D efforts within ultrasound and microbubbles performed by the former world leading diagnostic company; Nycomed Imaging AS (now GE Healthcare). In the late 1990’s and early 2000’s the core technology behind ACT® was developed, with more than $10 M and 40 man-years invested into establishing formulation, manufacturing line, quality control etc.

Year founded

---

2012

Served area

---

Worldwide

Headquarters

---

Østre Aker vei 19, 0581 Oslo – Norway

Shares outstanding

---

29,997,219

IPO

---

July 14, 2020

Stock exchange(s)

---

Euronext Oslo